AHA/ACC 2023 Chronic Coronary Disease Guideline: key recommendations

Who it applies to

Adults with established or suspected chronic coronary disease, including stable angina, prior MI, prior revascularization, and ischemic heart disease without obstructive coronary artery disease.

Key recommendations

• Emphasize a team-based approach combining lifestyle modification, cardiac rehabilitation, and medical therapy as the foundation of chronic coronary disease management.
• Use statin therapy as first-line lipid-lowering treatment, with addition of ezetimibe or PCSK9 inhibitors if LDL goals are not met in high-risk patients.
• Recommend antiplatelet therapy, generally aspirin monotherapy, in most patients with chronic coronary disease, with consideration of clopidogrel alone in select patients with aspirin intolerance.
• Beta-blockers are not recommended indefinitely in all patients with prior MI if there is no history of reduced ejection fraction, ongoing angina, or arrhythmia beyond the first year.
• Routine stress testing or anatomic imaging is not recommended in asymptomatic, stable patients without a change in clinical status.
• Revascularization is recommended mainly to improve symptoms in patients with significant angina despite medical therapy, rather than to reduce mortality in most stable presentations.
• SGLT2 inhibitors and GLP-1 receptor agonists are recommended in patients with chronic coronary disease and comorbid type 2 diabetes or heart failure to reduce cardiovascular events.
• Structured exercise-based cardiac rehabilitation is recommended for eligible patients to improve functional capacity and reduce cardiovascular risk.
• Screening for depression and psychosocial stressors is encouraged as part of comprehensive risk assessment given their association with worse cardiovascular outcomes.
• Ischemia with nonobstructive coronary arteries should still be managed with risk factor control and antianginal therapy as appropriate, rather than being dismissed as benign.

What is new in this edition

• Clarified that long-term beta-blocker use beyond one year after MI is not routinely required in the absence of reduced ejection fraction or recurrent ischemia.
• Expanded role for SGLT2 inhibitors and GLP-1 receptor agonists in patients with diabetes or heart failure overlapping with chronic coronary disease.
• Greater emphasis on individualized, symptom-driven decisions for revascularization versus medical therapy.
• Increased attention to ischemia with nonobstructive coronary arteries as a distinct entity requiring active management.

Practice points for students

• Not every patient with prior MI needs a beta-blocker forever; reassess ongoing indication after the first year.
• Revascularization in stable chronic coronary disease is primarily about symptom relief, not survival benefit, in most patients.
• Address lipid, glycemic, and blood pressure control aggressively using newer agents (SGLT2i, GLP-1 RA, PCSK9i) when comorbidities overlap.
• Don't ignore ischemia with nonobstructive coronary arteries as a diagnosis; it still warrants medical management.
• Routine surveillance stress testing in asymptomatic stable patients adds little value and is discouraged.

Condition

Other guidelines on this topic

• 2024 ESC Guidelines for the management of chronic coronary syndromesESC2024Summary
• Stable angina: management (CG126)NICE2016Summary

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by AHA/ACC. It is not medical advice: always read the original guideline before applying it to patients.